Breaking News

You are here » Indian-Commodity  :  Commodities  :  Jeera  :  Jeera futures trade slightly higher on NCDEX

15-Feb2018

Jeera futures trade slightly higher on NCDEX

Jeera futures traded slightly higher on NCDEX, due to technical buying at prevailing low rates by stockists amid anticipations of increased demand in new season. However, some gains remained capped on increased arrivals of cumin from growing belts. 

The contract for March delivery was trading at Rs 15950.00, up by 0.35% or Rs 55.00 from its previous closing of Rs 15895.00. The open interest of the contract stood at 10548 lots.

The contract for April delivery was trading at Rs 16225.00, rose 0.37% or Rs 60.00 from its previous closing of Rs 16165.00. The open interest of the contract stood at 2031 lots on NCDEX.


Related News

View all news

Jeera futures trade bearish on profit taking

Jeera futures traded bearish on NCDEX, with the profit booking by investors after the cumin prices rose due to firm physical domestic and exports demands from China and Bangladesh coupled......

Jeera futures surge on production concern

Jeera futures surged on NCDEX, due to technical buying by stockists and retailers amid expectations of lower production with the scanty rains in the cumin producing districts of Gujarat. Moreover, steady......

Jeera futures trade lower on NCDEX

Jeera futures traded lower on NCDEX, as traders locked-in their gains in conjunction with dip in export demands at prevailing higher price levels. Further, increased arrivals and good stocks also weighed......

Top News

View all news

Bhansali Engineering Polymers reports 33% fall in Q2 net profit

Bhansali Engineering Polymers has reported results for second quarter ended September 30, 2018.The company has reported 32.71% fall in its net profit at Rs 16.89 crore for the quarter under review as compared......

Biocon, Mylan N.V. receive positive CHMP opinion for Ogivri

Biocon and Mylan N.V. have announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Ogivri, a biosimilar......

Lupin Neurosciences receives positive CHMP opinion for NaMuscla

Lupin Neurosciences, a specialty pharma division of Lupin has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA),......